Financial giants have made a conspicuous bearish move on Viking Therapeutics. Our analysis of options history for Viking Therapeutics VKTX revealed 10 unusual trades.
Delving into the details, we found 30% of traders were bullish, while 60% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $662,541, and 4 were calls, valued at $247,670.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $45.0 to $65.0 for Viking Therapeutics during the past quarter.
Volume & Open Interest Trends
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Viking Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Viking Therapeutics's whale trades within a strike price range from $45.0 to $65.0 in the last 30 days.
Viking Therapeutics Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VKTX | PUT | TRADE | BEARISH | 08/16/24 | $5.0 | $4.2 | $4.8 | $49.00 | $299.5K | 721 | 632 |
| VKTX | PUT | TRADE | BULLISH | 07/26/24 | $2.3 | $2.2 | $2.2 | $47.00 | $197.1K | 211 | 15 |
| VKTX | CALL | TRADE | BULLISH | 08/16/24 | $4.1 | $3.8 | $4.1 | $55.00 | $154.5K | 1.4K | 549 |
| VKTX | PUT | SWEEP | BEARISH | 07/26/24 | $2.2 | $1.95 | $2.2 | $48.00 | $57.8K | 368 | 280 |
| VKTX | PUT | TRADE | BEARISH | 01/16/26 | $18.0 | $15.6 | $18.0 | $50.00 | $54.0K | 157 | 1 |
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
After a thorough review of the options trading surrounding Viking Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Where Is Viking Therapeutics Standing Right Now?
- Currently trading with a volume of 1,374,157, the VKTX's price is down by -1.36%, now at $50.84.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 0 days.
What Analysts Are Saying About Viking Therapeutics
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $105.0.
- An analyst from Morgan Stanley has revised its rating downward to Overweight, adjusting the price target to $105.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Viking Therapeutics options trades with real-time alerts from Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
